home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9409d.zip
/
M9490672.TXT
< prev
next >
Wrap
Text File
|
1994-09-24
|
3KB
|
49 lines
Document 0672
DOCN M9490672
TI Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide
against rev from human immunodeficiency virus type 1 in the adult male
rat following single injections and continuous infusion.
DT 9411
AU Iversen PL; Mata J; Tracewell WG; Zon G; Department of Pharmacology,
University of Nebraska Medical; Center, Omaha 68198-6260.
SO Antisense Res Dev. 1994 Spring;4(1):43-52. Unique Identifier : AIDSLINE
MED/94339691
AB An antisense phosphorothioate oligodeoxynucleotide 27-mer complementary
to the rev gene mRNA of the human immunodeficiency virus (HIV-1) was
administered to rats through intravenous injections and subcutaneous
infusions in order to investigate the disposition of this compound. In
addition, nonlethal toxic responses of the rat were evaluated. A
biphasic plasma clearance with t1/2 alpha of 20-25 min and t1/2 beta of
27-41 hr was observed. Single doses ranging from 35 to 3257 micrograms
were examined, and the plasma concentration and area under the plasma
concentration-time curve (AUC) were found to be directly proportional to
the dose. Continuous subcutaneous infusion of 50 mg over 28 days was
also examined. The oligonucleotide is completely eliminated in the urine
over 3 days. Electrophoretic analysis demonstrated that the excreted
compound has the same mobility and UV-absorbance profile as the
administered compound. Measurement of accumulation and distribution into
tissues revealed unique tissue-specific rates and extent of
oligonucleotide movement into and out of tissues. Results of the chronic
infusion study suggest that uptake into tissue is not saturated, even
after 28 days of infusion. Analysis of blood plasma from
oligonucleotide-treated animals shows a possible transient elevation in
levels of lactate dehydrogenase (LDH), alanine aminotransferase (ALT),
and aspartate aminotransferase (AST), but not alkaline phosphatase (AP),
gamma-glutamyltransferase (GT), and bilirubin. The data collectively
support the potential utility of phosphorothioate oligonucleotides as
therapeutic agents in vivo.
DE Alanine Aminotransferase/BLOOD Alkaline Phosphatase/BLOOD Animal
Aspartate Aminotransferase/BLOOD Base Sequence Bilirubin/BLOOD
Chromatography, High Pressure Liquid Gene Expression Regulation, Viral
*Genes, rev HIV-1/*GENETICS Injections, Intravenous Injections,
Subcutaneous Lactate Dehydrogenase/BLOOD Male Molecular Sequence Data
Oligonucleotides, Antisense/ADMINISTRATION & DOSAGE/
*PHARMACOKINETICS/TOXICITY Rats Rats, Sprague-Dawley RNA,
Messenger/METABOLISM Thionucleotides/ADMINISTRATION &
DOSAGE/*PHARMACOKINETICS/ TOXICITY Tissue Distribution JOURNAL
ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).